Insulin resistance: a global epidemic in need of effective therapies

被引：16

作者：

Califf, RM ^{[1
]}

机构：

[1] Duke Clin Res Inst, Durham, NC 27710 USA

来源：

EUROPEAN HEART JOURNAL SUPPLEMENTS | 2003年 / 5卷 / 0C期

关键词：

cardiovascular risk; impaired glucose; tolerance; metabolic syndrome; nateglinide; valsartan;

D O I：

10.1016/S1520-765X(03)90045-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is a worldwide rapid increase in the prevalence of type 2 diabetes, due to factors such as improved affluence, Longevity, and obesity. To prevent the development of diabetes, individuals must be identified at an early stage of risk and targeted with preventive measures such as lifestyle advice and pharmacological therapy. A key indicator of risk is impaired glucose tolerance. We have recently begun the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial to gather epidemiological data and provide insight into the protective effects of the angiotensin receptor blocker valsartan in patients with improved glucose intolerance. (C) 2003 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

引用

页码：C13 / C18

页数：6

共 36 条

[31] TREATMENT OF OBESITY BY MODERATE AND SEVERE CALORIC RESTRICTION - RESULTS OF CLINICAL RESEARCH TRIALS [J].